ISCO International Stem Cell Corporation (QB)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES                                                                                   
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940                       

1. Name and Address of Reporting Person * Don Wright	2. Issuer Name and Ticker or Trading Symbol International Stem Cell CORP [ ISCO.OB ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director                    _____ 10% Owner _____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle) C/O INTERNATIONAL STEM CELL CORP., 5950 PRIESTLY DRIVE	3. Date of Earliest Transaction (MM/DD/YYYY) 6/23/2020
(Street) CARLSBAD, CA 92008 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.08	6/23/2020		A		46428		(1)	6/23/2030	Common Stock	46428	$0	46428	D
Stock Option (Right to Buy)	$1.08	6/23/2020		A		30000		(2)	6/23/2030	Common Stock	30000	$0	30000	D

Explanation of Responses:
(1)	Stock option granted as part of compensation for non-employee directors. Options vest in four equal quarterly increments, with first increment vesting on 9/23/2020.
(2)	Stock option granted as part of compensation for non-employee directors. Options vest fully at the earlier of (i) June 23, 2021 or (ii) the date of the 2021 Annual Meeting of Stockholders, with vesting accelerated for all shares in the event of a change in control.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Don Wright C/O INTERNATIONAL STEM CELL CORP. 5950 PRIESTLY DRIVE CARLSBAD, CA 92008	X

Signatures
/s/ Sophia Garnette, Attorney-in-Fact		6/24/2020
**Signature of Reporting Person		Date